Clinical Trials Browser

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Phase 1 Recruiting

30 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT06088290 2026-05-15

SaLuDo

Phase 3 Active not recruiting

455 enrolled

Sarcoma

Leiomyosarcoma, Neoplasms

NCT07194044 2026-05-15

METTSEO

Phase 1 Recruiting

15 enrolled

Sarcoma

Sarcoma, Ewing

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT02180867 2026-05-04

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Phase 2/3 Active not recruiting

140 enrolled 22 charts

Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Granuloma, Plasma Cell, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Chondrosarcoma, Mesenchymal, Dermatofibrosarcoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Nerve Sheath Neoplasms, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Perivascular Epithelioid Cell Neoplasms

NCT01871766 2026-04-24

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Phase 2 Active not recruiting

115 enrolled

Sarcoma

Rhabdomyosarcoma

NCT07243626 2026-04-24

Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma

Phase 2 Recruiting

25 enrolled

Sarcoma

NCT04968106 2026-04-21

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Phase 2 Recruiting

45 enrolled

Sarcoma

Neoplasm Metastasis, Osteosarcoma

NCT07460986 2026-03-10

BEXAR

Phase 1/2 Not yet recruiting

278 enrolled

Sarcoma

NCT05218499 2026-03-02

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Phase 2/3 Completed

400 enrolled 15 charts

Sarcoma

Liposarcoma

NCT04199026 2026-02-19

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Phase NA Recruiting

20 enrolled

Sarcoma

NCT06820957 2026-02-17

Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

Phase 2/3 Active not recruiting

437 enrolled

Sarcoma

Sarcoma, Ewing

NCT07125183 2026-02-05

Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

Phase 2 Recruiting

20 enrolled

Sarcoma

Leiomyosarcoma, Sarcoma

NCT01231906 2026-01-23

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Phase 3 Completed

642 enrolled 11 charts

Sarcoma

Localized Extraskeletal Ewing Sarcoma

NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Phase 2 Terminated

71 enrolled

GynecologicSarcoma

Advanced Endometrial Cancer

NCT06220032 2026-01-05

HO170DLBCL

Phase 3 Recruiting

324 enrolled

LymphoidSarcoma

Heart Failure, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating, Cardiotoxicity

NCT06835049 2025-12-30

TNT-HYPE

Phase 2 Recruiting

24 enrolled

Sarcoma

Hyperthermia, Sarcoma

NCT07027423 2025-12-01

BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas

Phase 1 Not yet recruiting

32 enrolled

Sarcoma

NCT02811523 2025-11-26

In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma

Phase 1 Recruiting

17 enrolled

Sarcoma

Bone Neoplasms, Sarcoma

NCT07231250 2025-11-19

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Phase 2 Not yet recruiting

40 enrolled

Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT03805022 2025-10-02

CIRSARC

Phase 3 Recruiting

351 enrolled

Sarcoma

NCT04776525 2025-08-14

Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma

Phase 2 Recruiting

49 enrolled

Sarcoma

NCT04874311 2025-08-13

TRUST

Phase 2 Recruiting

80 enrolled

Sarcoma

Tertiary Lymphoid Structures, Neoplasm Metastasis, Sarcoma

NCT05858710 2025-07-28

Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma

Phase 1 Completed

8 enrolled

Sarcoma

NCT01027910 2025-07-24

PCI-24781 in Combination With Doxorubicin to Treat Sarcoma

Phase 1/2 Completed

20 enrolled 10 charts

Sarcoma

NCT06277154 2025-07-24

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Phase 2 Recruiting

148 enrolled

GynecologicSarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Endometrial Stromal, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

NCT02451943 2025-07-15

ANNOUNCE

Phase 3 Completed

509 enrolled 23 charts

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT07034508 2025-06-24

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

Phase 2 Not yet recruiting

134 enrolled

Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT00470223 2025-06-08

OS2006

Phase 3 Active not recruiting

318 enrolled

Sarcoma

Sarcoma, Osteosarcoma

NCT03719430 2025-04-29

APX005M and Doxorubicin in Advanced Sarcoma

Phase 2 Active not recruiting

27 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Neurofibrosarcoma

NCT06524583 2025-03-30

L-UteCIN

Phase 2 Recruiting

198 enrolled

Sarcoma

Leiomyosarcoma Uterus

NCT04757337 2025-03-25

GERICO14

Phase 3 Recruiting

214 enrolled

Sarcoma

NCT04213794 2025-02-20

TOASTIT

Phase EARLY_PHASE1 Terminated

2 enrolled

GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Colonic Neoplasms, Fallopian Tube Neoplasms, Liposarcoma, Ovarian Neoplasms, Pelvic Neoplasms, Rectal Neoplasms, Rhabdomyosarcoma, Sarcoma, Stomach Neoplasms, Desmoplastic Small Round Cell Tumor

NCT05100628 2025-01-06

A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma

Phase 1 Terminated

9 enrolled 10 charts

Sarcoma

NCT04996004 2024-12-11

TTI-621-03

Phase 2 Terminated

76 enrolled 53 charts

Sarcoma

Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Dermatofibrosarcoma

NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Phase 1/2 Recruiting

358 enrolled

DermatologicGastrointestinalGenitourinarySarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT03277924 2024-08-13

ImmunoSarc

Phase 1/2 Completed

197 enrolled

Sarcoma

Chondrosarcoma, Extraskeletal Myxoid, Bone Neoplasms, Chondrosarcoma, Hemangioendothelioma, Hemangiosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Hemangioendothelioma, Epithelioid, Histiocytoma, Malignant Fibrous, Solitary Fibrous Tumors

Clinical Trials

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

SaLuDo

METTSEO

I-SPY

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma

TORNADO

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Bevacizumab/Doxorubicin/Radiation for Sarcoma

IPIAP-STM

Lurbinectedin + Doxorubicin In Leiomyosarcoma

9-ING-41 in Patients With Advanced Cancers

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

BEXAR

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

HO170DLBCL

TNT-HYPE

BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas

In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

CIRSARC

Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma

TRUST

Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma

PCI-24781 in Combination With Doxorubicin to Treat Sarcoma

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

ANNOUNCE

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

OS2006

APX005M and Doxorubicin in Advanced Sarcoma

L-UteCIN

GERICO14

TOASTIT

A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma

TTI-621-03

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

ImmunoSarc